Investor Center

Management and Advisory Team

Management

Scientific Team

Chip is the visionary of BioStem Technologies and has run a variety of businesses over the past three decades as owner or partner, including online retail, brick and mortar retail, TV content production, and distribution, along with producing and licensing technologies to global manufacturers such as Volvo. He has also served as lead negotiator in multiple deals with fortune 500 companies.  As a brain tumor survivor and a catastrophic near-fatal accident survivor, he leads the Company with a unique understanding of the patients’ perspective. With Mr. Van Vurst’s empathy for patients who seek healing, his passion for new product development, his personal experience with stem cell treatment success, and his diverse experience in running multiple strategic business units simultaneously, he is ideally suited to lead this transformational company.

CEO & Founder

Chip Van Vurst

Jason is the Chief Compliance Officer of BioStem and is also a Director and Co-Founder. He began his engineering career at the age of 15 working as a data analysis engineer for top-tier auto racing teams, including Turner Motorsports’ BMW team. It was on the racing circuit where he originally met the Van Vursts, and Chip was struck by the fact that he was 15 years younger than his peers. He holds a B.S. in Mechanical Engineering and a minor in Business Administration from the highly ranked Milwaukee School of Engineering, and he is Six Sigma Black Belt certified. Mr. Matuszewski became interested in biotech after working with the Juvenile Diabetes Research Foundation, and this inspired him to join the VanVurst’s in co-founding BioStem. As CFO, Mr. Matuszewski helped engineer the purchase and restructure of the public vehicle that is now listed as BSEM.

Chief Financial Officer & Co-Founder

Jason Matuszewski

Andrew is the Chief Operating Officer, Director and Co-Founder of BioStem. At the age of 14, he entered Florida Atlantic University; at the age of 19, he joined the Marine Corps where he trained in Heavy-Helicopter Training Squadron-302 and was responsible for daily operations and inspections on the Sikorsky CH-53E. After a successful career in the Marines, Mr. Van Vurst continued his education through Landmark Worldwide, completing its advanced programs. During this time, he co-founded an assets acquisitions company where he analyzed distressed companies, looking for opportunities to purchase, redesign, and create more value for shareholders. In August of 2014, he co-founded BioStem Technologies.

Chief Operating Officer & Co-Founder

Andrew Van Vurst

Mr. Espositio is one of the top pharmaceutical operations executives in the industry. He holds a BS in Chemistry and an MS in Organic Chemistry from Southern Connecticut State University. He was an award-winning Chemist and Development Chemist for Uniroyal, where he spent a decade in senior-and-executive management positions, running various pharmaceutical manufacturing operations. As President of the Pharmaceuticals unit, he is responsible for the development and formulation of all our pharmaceuticals and API repackaging products.

President of QPI

Joe Esposito

Dr. Watson is a member of the scientific advisory board and expert in biomedical research, became a faculty member in the Departments of Neurology and Biomedical Engineering at the University of Miami School of Medicine in 1980, and was promoted to full professor in 1998. He holds a B.A. in Physics and Mathematics from Miami University (Ohio) and a Ph.D. in Nuclear Physics from Florida State University in 1970. He is the author of 91 peer-reviewed articles in professional journals, 25 book chapters, and 110 meeting abstracts on a range of topics that include cancer cytology, ophthalmology and, chiefly, cerebrovascular diseases (stroke) and spinal cord injury. The common theme of his work is photochemically-induced free radical chemistry and lipid peroxidation to induce thrombosis of arteries and veins, and dissolution of such thrombi by photophysically induced nitric oxide. He is a named inventor on two U.S. Patents and has another application in development. Dr. Watson’s research was funded by the National Institute of Neurological Diseases and Stroke for 22 years.

Scientific Advisory Board

Dr. Brant Watson

Dr. Barbara Krutchkoff, PhD., is a leading consultant for physicians and biomedical start-up companies in regenerative and cellular medicine. She is Executive Director of the Institute of Regenerative and Cellular Medicine (the “IRCM”), and Co-Chair of the IRCM IRB, which provides support for translational research and validation of regenerative therapies. She has spent more than 25 years helping university and industry leaders to bring regenerative medicine safely to patients. Her educational credentials include Physics and Computer Science at the University of Florida, graduate level biomedical engineering at Virginia Tech, a PhD in behavioral psychology, a Doctorate in Integrative Medicine, and Stem Cell Fellowships at UCLA and A4M. She is a board-certified Diplomat and a Fellow of the American Board of Regenerative Medicine. She is also an adjunct professor at the Universite Paris Descartes, and Chair of the IRCM/Regenerative Outcomes committee for the NIH (National Institutes of Health) Orthopedic Registry. 

Scientific Advisory Board

Dr. Barbara Krutchkoff

Dr. Jennie Sandqvist is a leading neurologist in Sweden. She has a medical degree from Semmelweis Medical School in Hungary, with a specialty in neurology. She served as Chief of Neurology at the Karolinska University Hospital in Stockholm-Sweden for seven years, and is currently the Chief of Neurology at the Neurological Rehab Station in Stockholm.

Scientific Advisory Board

Dr. Jennie Sandqvist

Dr. Huber is an MD (German and Havard Medical School) and serial entrepreneur with over 25 years of experience in the healthcare industry. As CEO she built up Visumed for laser refractive surgery with 10 centers und 80 ophthalmological users in Germany. Working as the director (shareholder) of DP-Medsystems she built-up the hospital and clinic marketing department. She is the interim manager for reorganization and business development projects of big outpatient centers and hospitals as well as business angel and consultant for medical start-ups and investors. 

Scientific Advisory Board

Dr. Irmgard Huber

Dr. Felix Amon has two decades of product management, medical innovation and business development experience in healthcare and related industries, including three years as a Product Manager for Eli Lilly, 2 years as the Austria Marketing and Sales Director for Merck (MSD) Europe. This was followed by leading the Ophthalmics business in Merck’s ww Headquarter in Whitehouse Station, New Jersey where he managed Planning and Project Management for a $650 million business operating in 104 countries. He also completed the development of an European Sales and Marketing Campaign for BIOGEN’s Avonex and implemented the launch of Avonex in Germany, Austria and Switzerland. Dr. Amon has an MBA (1987) from Emory University in Atlanta, Georgia, and a PhD in Law (1985) from Linz – Johannes Keppler University in Austria.

Scientific Advisory Board

Dr. Felix Amon